GlassScriptPhysician profile
Fatma V Deif
NPI 1538553508
$6,830.74
in general payments reported to CMS, 2019-2025
36 companies · $1,567 in 2025
The $1,567 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $488 · 2021: $374 · 2022: $792 · 2023: $1,640 · 2024: $1,316 · 2025: $1,567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,522.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,063.63 | 2019-2025 | |
| Lilly USA, LLC | $987.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $936.16 | 2022-2025 | Otezla, Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $900.39 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $499.66 | 2024-2025 | Xifaxan |
| Novo Nordisk INC | $378.66 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Galderma Laboratories, L.P. | $354.70 | 2021-2025 | |
| Braemar Manufacturing, LLC | $254.87 | 2019 | |
| Abbvie INC. | $195.37 | 2022 | |
| Astellas Pharma US INC | $124.10 | 2019-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.30 | 2023-2024 | Jardiance |
| Idorsia Pharmaceuticals US INC | $98.20 | 2023-2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $87.31 | 2019-2023 | |
| Inspire Medical Systems, INC. | $76.39 | 2023-2025 | Inspire |
| Phadia US INC. | $70.45 | 2021-2023 | Immunocap |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fatma Deif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.